Kazunori Hirokawa Executive Vice President and CFO PLAY LIST from the beginning Top Management Presentation Financial Results of FY2017 Q1 Forward-Looking Statements Agenda FY2017 Q1 Financial Results Overview of FY2017 Q1 Results Revenue Operating Profit Profit Attributable to Owners of the Company Revenue: Major Business Units (Incl. Forex impact) Revenue: Major Products in Japan Major Management Topics Edoxaban Update Growth in Japan Growth in Japan Growth in Germany and South Korea LCM update Japan Business Update Expansion of Product Portfolio in Japan Expansion of Product Portfolio in Japan Injectafer Update Growth of Injectafer Injectafer Life-Cycle Management Business Growth in China Establish Efficient Structures and Expand Revenue Enhance Production Capacity for Business Expansion R&D Update Mirogablin: Phase 3 Result and Future Schedule Presentation at ASCO 2017 DS-8201: ASCO 2017 (Oral) DS-8201: ASCO 2017 (Oral) DS-8201: ASCO 2017 (Oral) DS-8201: ASCO 2017 (Oral) DS-8201: ASCO 2017 (Oral) DS-8201: ASCO 2017 (Oral) DS-8201: ASCO 2017(Poster) U3-1402: ASCO 2017 (Poster) DS-8201: Future Schedule U3-1402: Future Schedule DS R&D Day 2017 FY2017 Major R&D Milestone Events Major R&D Pipeline @ Q&A Q&A 1 Q&A 2 Q&A 3 Q&A 4 Q&A 5 Back Next